Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR).

被引：0
|
作者：
Piazza, R
Magistroni, V
Tornaghi, L
Andreoni, F
Bungaro, S
Cazzaniga, G
Biondi, A
Pogliani, E
Varella-Garcia, M
Corneo, G
Gambacorti-Passerini, C
机构：
[1] Natl Canc Inst, I-20133 Milan, Italy
[2] Univ Milano Bicocca, Osped San Gerardo, Monza, Italy
[3] Univ Colorado, Ctr Canc, Denver, CO 80262 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4996
引用
收藏
页码：319B / 319B
页数：1
相关论文
共 50 条
  • [1] Dasatinib Is Associated with Rapid and Durable Complete Hematologic Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
    Liu, Delong
    Matloub, Yousif
    Mulchopadhyay, Jaydip
    Liu, David
    Goldberg, Stuart L.
    BLOOD, 2008, 112 (11) : 741 - 741
  • [2] Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib
    Yang, Allen S.
    Jillella, Anand
    Miller, Carole B.
    Akard, Luke P.
    DeAngelo, Daniel J.
    Goldberg, Stuart L.
    Williams, Denise
    Radich, Jerald P.
    BLOOD, 2009, 114 (22) : 868 - 869
  • [3] Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
    A Hochhaus
    M Baccarani
    M Deininger
    J F Apperley
    J H Lipton
    S L Goldberg
    S Corm
    N P Shah
    F Cervantes
    R T Silver
    D Niederwieser
    R M Stone
    H Dombret
    R A Larson
    L Roy
    T Hughes
    M C Müller
    R Ezzeddine
    A M Countouriotis
    H M Kantarjian
    Leukemia, 2008, 22 : 1200 - 1206
  • [4] Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
    Hochhaus, A.
    Baccarani, M.
    Deininger, M.
    Apperley, J. F.
    Lipton, J. H.
    Goldberg, S. L.
    Corm, S.
    Shah, N. P.
    Cervantes, F.
    Silver, R. T.
    Niederwieser, D.
    Stone, R. M.
    Dombret, H.
    Larson, R. A.
    Roy, L.
    Hughes, T.
    Mueller, M. C.
    Ezzeddine, R.
    Countouriotis, A. M.
    Kantarjian, H. M.
    LEUKEMIA, 2008, 22 (06) : 1200 - 1206
  • [5] Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase (CML-CP)
    Kantarjian, Hagop M.
    Druker, Brian J.
    Guilhot, Francois
    Cortes, Jorge
    O'Brien, Stephen G.
    Krahnke, Tillmann
    Larson, Richard A.
    BLOOD, 2007, 110 (11) : 317A - 317A
  • [6] Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib
    Hochhaus, Andreas
    Mueller, Martin C.
    Radich, Jerald
    Branford, Susan
    Hanfstein, Benjamin
    Rousselot, Philippe
    Lipton, Jeffrey H.
    Bleickardt, Eric
    Sinha, Ritwik
    Hughes, Timothy P.
    BLOOD, 2008, 112 (11) : 400 - 400
  • [7] Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern
    Cortes, Jorge E.
    Jiang, Qian
    Wang, Jianxiang
    Weng, Jianyu
    Zhu, Huanling
    Liu Xiaoli
    Hochhaus, Andreas
    Kim, Dong-Wook
    Radich, Jerald
    Savona, Michael R.
    Regueira, Patricia Martin
    Sy, Oumar
    Gurnani, Renuka
    Saglio, Giuseppe
    BLOOD, 2018, 132
  • [8] Efficacy and Safety of Nilotinib in elderly patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance
    Ottmann, O. G.
    le Coutre, P.
    Gattermann, N.
    Hochhaus, A.
    Bruemmendorf, T. H.
    Kindler, T.
    Duyster, J.
    Al-Ali, H.
    Lipton, J.
    Wang, J.
    Yang, M.
    Szczudlo, T.
    Giles, F.
    ONKOLOGIE, 2010, 33 : 138 - 138
  • [9] Imatinib plasma concentration and sokal risk score are independently prognostic for complete cytogenetic response (CCyR) in patients with chronic phase chronic myeloid leukemia (CML-CP)
    Larson, Richard A.
    Druker, Brian J.
    Guilhot, Francois
    O'Brien, Stephen G.
    Krahnke, Tillman
    Gathmann, Insa
    Wang, Yanfeng
    BLOOD, 2007, 110 (11) : 574A - 575A
  • [10] A transcriptomal profile for predicting complete cytogenetic response (CCR) in chronic phase CML patients treated with imatinib
    McWeeney, Shannon K.
    Pemberton, Lucy C.
    Harrington, Chris A.
    Druker, Brian J.
    Deminger, Michael W.
    BLOOD, 2007, 110 (11) : 305A - 305A
12345